R Squared’s Lineage Cell Therapeutics LCTX Stock Holding History

R Squared’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,823	Closed	-$20K	–	633
2025 Q3	$20K	Buy	+11,823	New	+$14K	0.01%	528
2025 Q2	–	Sell	-11,150	Closed	-$5.04K	–	525
2025 Q1	$5.04K	Buy	+11,150	New	+$6.54K	0.01%	287

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

R Squared's LCTX Position: Q4 2025 in Review

R Squared sold out of Lineage Cell Therapeutics (LCTX) in Q4 2025, closing a stake of 11,823 shares — an estimated $20K sold.

R Squared first reported a position in LCTX in Q1 2025 and held it in 2 quarters. The position peaked at $20K in Q3 2025. 123 funds tracked by Wall St. Rank hold LCTX as of Q4 2025.

R Squared reported no remaining Lineage Cell Therapeutics position as of Q4 2025 after selling out during the quarter.
R Squared sold 11,823 Lineage Cell Therapeutics shares in Q4 2025, an estimated $20K.
R Squared first reported a position in Lineage Cell Therapeutics in Q1 2025 and held it in 2 quarters.
R Squared's Lineage Cell Therapeutics position peaked at $20K in Q3 2025.
123 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2025.

Based on R Squared's 13F filing for Q4 2025, filed 30 Jan 2026.